ScholarIQanswers from OpenAlex

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

PaperCitations, authors & open-access status

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy have?

ScholarIQcitation count

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy has 1,358 citations in the OpenAlex counts ScholarIQ stores.

When was CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy published?

ScholarIQyear

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy has 2017 year in the ScholarIQ index.

What is the open-access status of CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy?

ScholarIQoa status

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy has closed oa status in the ScholarIQ index.

What is the DOI of CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy?

ScholarIQdoi

The DOI for CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy is on the source record.

What is the PMID of CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy?

ScholarIQpmid

The PMID for CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy is on the source record.

What is the OpenAlex record for CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy?

ScholarIQopenalex

The OpenAlex for CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial